|
||||||
|
 | |
| |
| |
| |
| |
|
Fusion gene ID: 3651 |
FusionGeneSummary for AXIN1_BBX |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: AXIN1_BBX | Fusion gene ID: 3651 | Hgene | Tgene | Gene symbol | AXIN1 | BBX | Gene ID | 8312 | 56987 |
| Gene name | axin 1 | BBX, HMG-box containing | |
| Synonyms | AXIN|PPP1R49 | ARTC1|HBP2|HSPC339|MDS001 | |
| Cytomap | 16p13.3 | 3q13.12 | |
| Type of gene | protein-coding | protein-coding | |
| Description | axin-1axis inhibition protein 1axis inhibitor 1fused, mouse, homolog ofprotein phosphatase 1, regulatory subunit 49 | HMG box transcription factor BBXAg recognized by Treg cells 1HMG box-containing protein 2bobby sox homologx 001 protein | |
| Modification date | 20180522 | 20180519 | |
| UniProtAcc | O15169 | Q8WY36 | |
| Ensembl transtripts involved in fusion gene | ENST00000262320, ENST00000354866, ENST00000481769, | ENST00000415149, ENST00000402543, ENST00000325805, ENST00000416476, ENST00000406780, ENST00000473542, | |
| Fusion gene scores | * DoF score | 11 X 4 X 8=352 | 10 X 12 X 6=720 |
| # samples | 12 | 14 | |
| ** MAII score | log2(12/352*10)=-1.55254102302878 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(14/720*10)=-2.36257007938471 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
| Context | PubMed: AXIN1 [Title/Abstract] AND BBX [Title/Abstract] AND fusion [Title/Abstract] | ||
| Functional or gene categories assigned by FusionGDB annotation | Tumor suppressor gene involved fusion gene, retained protein feature but frameshift. DDR (DNA damage repair) gene involved fusion gene, in-frame but not retained their domain. | ||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Hgene | AXIN1 | GO:0001934 | positive regulation of protein phosphorylation | 9601641 |
| Hgene | AXIN1 | GO:0030178 | negative regulation of Wnt signaling pathway | 10644691 |
| Hgene | AXIN1 | GO:0032147 | activation of protein kinase activity | 9601641 |
| Hgene | AXIN1 | GO:0034622 | cellular protein-containing complex assembly | 16601693 |
| Hgene | AXIN1 | GO:0045732 | positive regulation of protein catabolic process | 9601641 |
| Fusion gene information from three resources (ChiTars (NAR, 2018), tumorfusions (NAR, 2018), Gao et al. (Cell, 2018)) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Data type | Source | Cancer type | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| TCGA | RV | OV | TCGA-61-2109-01A | AXIN1 | chr16 | 396148 | - | BBX | chr3 | 107466812 | + |
| * LD: Li Ding group's fusion gene list RV: Roel Verhaak group's fusion gene list ChiTaRs fusion database |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| Frame-shift | ENST00000262320 | ENST00000415149 | AXIN1 | chr16 | 396148 | - | BBX | chr3 | 107466812 | + |
| Frame-shift | ENST00000262320 | ENST00000402543 | AXIN1 | chr16 | 396148 | - | BBX | chr3 | 107466812 | + |
| Frame-shift | ENST00000262320 | ENST00000325805 | AXIN1 | chr16 | 396148 | - | BBX | chr3 | 107466812 | + |
| Frame-shift | ENST00000262320 | ENST00000416476 | AXIN1 | chr16 | 396148 | - | BBX | chr3 | 107466812 | + |
| Frame-shift | ENST00000262320 | ENST00000406780 | AXIN1 | chr16 | 396148 | - | BBX | chr3 | 107466812 | + |
| 5CDS-intron | ENST00000262320 | ENST00000473542 | AXIN1 | chr16 | 396148 | - | BBX | chr3 | 107466812 | + |
| Frame-shift | ENST00000354866 | ENST00000415149 | AXIN1 | chr16 | 396148 | - | BBX | chr3 | 107466812 | + |
| Frame-shift | ENST00000354866 | ENST00000402543 | AXIN1 | chr16 | 396148 | - | BBX | chr3 | 107466812 | + |
| Frame-shift | ENST00000354866 | ENST00000325805 | AXIN1 | chr16 | 396148 | - | BBX | chr3 | 107466812 | + |
| Frame-shift | ENST00000354866 | ENST00000416476 | AXIN1 | chr16 | 396148 | - | BBX | chr3 | 107466812 | + |
| Frame-shift | ENST00000354866 | ENST00000406780 | AXIN1 | chr16 | 396148 | - | BBX | chr3 | 107466812 | + |
| 5CDS-intron | ENST00000354866 | ENST00000473542 | AXIN1 | chr16 | 396148 | - | BBX | chr3 | 107466812 | + |
| intron-3CDS | ENST00000481769 | ENST00000415149 | AXIN1 | chr16 | 396148 | - | BBX | chr3 | 107466812 | + |
| intron-3CDS | ENST00000481769 | ENST00000402543 | AXIN1 | chr16 | 396148 | - | BBX | chr3 | 107466812 | + |
| intron-3CDS | ENST00000481769 | ENST00000325805 | AXIN1 | chr16 | 396148 | - | BBX | chr3 | 107466812 | + |
| intron-3CDS | ENST00000481769 | ENST00000416476 | AXIN1 | chr16 | 396148 | - | BBX | chr3 | 107466812 | + |
| intron-3CDS | ENST00000481769 | ENST00000406780 | AXIN1 | chr16 | 396148 | - | BBX | chr3 | 107466812 | + |
| intron-intron | ENST00000481769 | ENST00000473542 | AXIN1 | chr16 | 396148 | - | BBX | chr3 | 107466812 | + |
Top |
FusionProtFeatures for AXIN1_BBX |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| AXIN1 | BBX |
| Component of the beta-catenin destruction complexrequired for regulating CTNNB1 levels through phosphorylation andubiquitination, and modulating Wnt-signaling (PubMed:12192039,PubMed:27098453). Controls dorsoventral patterning via twoopposing effects; down-regulates CTNNB1 to inhibit the Wntsignaling pathway and ventralize embryos, but also dorsalizesembryos by activating a Wnt-independent JNK signaling pathway(PubMed:12192039). In Wnt signaling, probably facilitates thephosphorylation of CTNNB1 and APC by GSK3B (PubMed:12192039).Likely to function as a tumor suppressor. Enhances TGF-betasignaling by recruiting the RNF111 E3 ubiquitin ligase andpromoting the degradation of inhibitory SMAD7 (PubMed:16601693).Also component of the AXIN1-HIPK2-TP53 complex which controls cellgrowth, apoptosis and development (PubMed:17210684). Facilitatesthe phosphorylation of TP53 by HIPK2 upon ultraviolet irradiation(PubMed:17210684). {ECO:0000269|PubMed:12192039,ECO:0000269|PubMed:16601693, ECO:0000269|PubMed:17210684,ECO:0000269|PubMed:27098453}. | Transcription factor that is necessary for cell cycleprogression from G1 to S phase. {ECO:0000269|PubMed:11680820}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at . * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
FusionGeneSequence for AXIN1_BBX |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. (nt: nucleotides, aa: amino acids) |
| * Fusion amino acid sequences. |
| * Fusion transcript sequences (only coding sequence (CDS) region). |
| * Fusion transcript sequences (Full-length transcript). |
Top |
FusionGenePPI for AXIN1_BBX |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in . |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| AXIN1 | SMYD2, GSK3B, CTNNB1, APC, DAB2, DVL3, AXIN1, GAK, UTP14A, ANP32A, CRMP1, EEF1A1, LRP5, CSNK1E, CSNK1A1, MAP3K1, TSC1, TSC2, DVL2, DVL1, PPP2R5A, AMER1, DAXX, BTRC, PRMT1, CARM1, MYC, GSK3A, PIN1, PPP2CA, STRAP, PML, TP53, HIPK2, SMURF2, HTT, AXIN2, LRP6, SKI, SKIL, SMAD7, NCK2, PPP1CA, UBC, ARRB1, CAV1, TNFAIP3, SMURF1, LMO2, MYOT, GNAS, MAP3K4, FBXW11, TNKS, XPO1, CSNK1D, CTNNA1, JUP, MAPRE1, PUF60, GAPVD1, ARHGAP21, MAP3K2, USP15, WDR26, FOXM1, WDYHV1, USP7, TRIM25 | BBX | NEDD4L, ELAVL1, APP, HSP90AA1, HDAC1, RPA3, RPA2, RPA1, SCGN, NIFK, HIST1H2BG, APC, CDC42, RAB5C, S100A4, FOXJ2, ARIH1, H2AFY2, GPATCH4, ZNF512, RSBN1, RPL18A, MECP2, TRIM44, PPP1R15A, ZSCAN31, SPAG1, TRIM25 |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
RelatedDrugs for AXIN1_BBX |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.0 2018-04-02) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
RelatedDiseases for AXIN1_BBX |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
| Hgene | AXIN1 | C2239176 | Liver carcinoma | 2 | CTD_human;HPO;UNIPROT |
Copyright 2018-Present -The University of Texas Health Science Center at Houston (UTHealth)
|